A practical reference on Angiotensin IV analog: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-10-29. Anything still debated is marked as such rather than presented as settled.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical lyophilized research form. |
| Solubility | Soluble in DMSO; limited in water | Depends on purity and salt form. |
| Storage temperature | -20 °C or lower | Desiccated and protected from light. |
| Analytical method | RP-HPLC and LC-MS | Common for purity and identity. |
| Regulatory status | Research chemical in many countries | Not widely approved as a medicine. |
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
=== Pharmacodynamics === Oveporexton acts as a selective agonist of the orexin OX2 receptor. Oveporexton has wakefulness-promoting effects in animals, including in rodents and monkeys. In addition, oveporexton has been found to be effective in the treatment of narcolepsy and cataplexy in phase 3 clinical trials in humans. Oveporexton is a first-in-class medication and targets the root symptomatic cause of narcolepsy type 1 by remediating the orexin (hypocretin) deficiency that is present in the condition.
Sara L. Goodacre is a research geneticist and Professor of Evolutionary Biology and Genetics at the University of Nottingham. She is the lead for the Open Air Laboratories, a citizen science project that engages people with the outdoor environment and Deputy Director of the Biotechnology and Biological Sciences Doctoral Training Programme.
We knew the world would not be the same. A few people laughed, a few people cried, and most people were silent. I remembered the line from the Hindu scripture the Bhagavad Gita. Vishnu is trying to persuade the prince that he should do his duty and to impress him takes on his multiarmed form and says, "Now, I am become Death, the destroyer of worlds." I suppose we all thought that one way or another.
== History == Dihexa was developed by Joseph Harding and his team at Washington State University. Later developments were done by M3 Biotechnology, a company founded to commercialize dihexa. Fosgonimeton, a phosphate pro-drug of dihexa is currently in clinical trials for the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's disease
== Parasites == Parasites include Plasmodium berghei (for which it also serves as a vector), and the bioinsecticides/entomopathogenic fungi Metarhizium robertsii and Beauveria bassiana. All three of these parasites combine with insecticides to reduce fitness – see § Insecticides below. CRISPR/Cas9 and U6-gRNA are increasingly (as of 2020) being used together for knockout experiments in mosquitoes. Dong et al., 2018 develops and presents a new U6-gRNA+Cas9 technique in An. gambiae, and utilizes it to knock out fibrinogen related protein 1 (FREP1), thereby severely reducing infection of the mosquito by P. berghei and P. falciparum. However this also demonstrates the centrality of FREP1 to the insect's success, impairing all measured activities across all life stages. Yang et al., 2020 uses the Dong method to do the same with mosGILT, also severely reducing Plasmodium infection of the mosquito but also finding a vital life process is impaired, in mosGILT's case ovary development.
Sources: en.wikipedia.org
=== Grow slow and moult model === The "grow slow and moult" model describes a potential mechanism of de novo gene birth, particular to protein-coding genes. In this scenario, existing protein-coding ORFs expand at their ends, especially their 3' ends, leading to the creation of novel N- and C-terminal domains. Novel C-terminal domains may first evolve under weak selection via occasional expression through read-through translation, as in the preadaptation model, only later becoming constitutively expressed through a mutation that disrupts the stop codon. Genes experiencing high translational readthrough tend to have intrinsically disordered C-termini. Furthermore, existing genes are often close to repetitive sequences that encode disordered domains. These novel, disordered domains may initially confer some non-specific binding capability that becomes gradually refined by selection. Sequences encoding these novel domains may occasionally separate from their parent ORF, leading or contributing to the creation of a de novo gene. Interestingly, an analysis of 32 insect genomes found that novel domains (i.e. those unique to insects) tend to evolve fairly neutrally, with only a few sites under positive selection, while their host proteins remain under purifying selection, suggesting that new functional domains emerge gradually and somewhat stochastically.
Skin flaps are an essential part of a surgeon's toolbox in plastic surgery. It is part of the reconstructive ladder. The first known report of surgical flaps comes from 600 BC, in India. The Sushruta records that the tilemakers' caste would reconstruct noses using regional flaps, due to the practice of nose amputations as a form of legal punishment. The next description of flap surgery comes from Celsus, an ancient Roman who described the advancement of skin flaps from 25 BC to 50 AD. In the 15th century, Gaspare Tagliacozzi, an Italian surgeon, helped develop the "Italian method" for nasal reconstruction: a delayed pedicle skin graft, where the skin from the arm would be attached to the nose for many months, to create the reconstruction. This was first printed in the 1597 book De Curtorum Chirurgia per Insitionem. The Italian method was rediscovered in 1800 by German surgeon Carl Ferdinand von Graefe. Major advancements in modern plastic surgery are mostly attributed to Harold Gillies, who pioneered facial reconstruction during World War I by using pedicled tube flaps on patients like Walter Yeo, and Gilles' cousin Archibald McIndoe, who developed the walking-stalk skin flap in 1930. With the introduction of the operating microscope, microvascular surgery advancements allowed for the anastomosis of blood vessels. This led to the ability of free tissue transfers and, in 1958, Bernard Seidenberg transferred a part of the jejunum to the esophagus, in order to remove a cancer.
=== Dairy products === Experiments conducted by introducing the strain ME-3 of L. fermentum into dairy products as a probiotic ingredient revealed that it was able to suppress the reputed contaminants of food such as pathogenic Salmonella spp., Shigella spp., and urinary tract infections that are caused by E. coli and Staphylococcus spp. Also the introduction of L. fermentum strains such as ME-3 in goat milk revealed that it was actually favorable to the host, resulting in an increase in number of beneficial lactobacilli.
Walker attended RMIT University in Melbourne, Australia. Together with John Cook and Ian Caughley, Walker started working on Team Fortress as a mod for id Software's QuakeWorld in 1996. Due to the popularity of the product, the team was hired by the then-small Valve to work on Team Fortress Classic and later on Team Fortress 2. Walker has played development roles in various Valve games, including Half-Life 2 and Dota 2. More recently, Walker has been focused on the collision of economics and game design, in an attempt to transform Team Fortress 2 into a free-to-play, microtransaction-based game. Walker worked on Valve's flagship virtual reality game, Half-Life: Alyx, released on 23 March 2020.
Sources: en.wikipedia.org
Wells refused the offered freedom of the town, stating: "Bromley has not been particularly gracious to me nor I to Bromley and I don't think I want to add the freedom of Bromley to the freedom of the City of London and the freedom of the City of Brussels – both of which I have." He described Bromley in one of his novels as a "morbid sprawl of population".
===== Light collector ===== Using graphene as a photoactive material requires its bandgap to be 1.4–1.9 eV. In 2010, single cell efficiencies of nanostructured graphene-based PVs of over 12% were achieved. According to P. Mukhopadhyay and R. K. Gupta organic photovoltaics could be "devices in which semiconducting graphene is used as the photoactive material and metallic graphene is used as the conductive electrodes". In 2008, chemical vapor deposition produced graphene sheets by depositing a graphene film made from methane gas on a nickel plate. A protective layer of thermoplastic is laid over the graphene layer and the nickel underneath is then dissolved in an acid bath. The final step is to attach the plastic-coated graphene to a flexible polymer sheet, which can then be incorporated into a PV cell. Graphene/polymer sheets range in size up to 150 square centimeters and can be used to create dense arrays. Silicon generates only one current-driving electron for each photon it absorbs, while graphene can produce multiple electrons. Solar cells made with graphene could offer 60% conversion efficiency.
== Nomenclature == Confusingly, there are two "standard" nomenclatures for FPR receptors and their genes, the first used, FPR, FPR1, and FPR2 and its replacement, FPR1, FPR2 (this gene), and FPR3. The latter nomenclature is recommended by the International Union of Basic and Clinical Pharmacology and is used here. Other previously used names for FPR1 are NFPR, and FMLPR; for FPR2 are FPRH1, FPRL1, RFP, LXA4R, ALXR, FPR2/ALX, HM63, FMLPX, and FPR2A; and for FPR3 are FPRH2, FPRL2, and FMLPY.
Sources: en.wikipedia.org
The lyophilized powder is generally stored at -20 °C or lower, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data may vary by formulation and purity.
Mass spectrometry is commonly used to confirm molecular mass, while RP-HPLC estimates purity. These methods can be combined with amino acid analysis or NMR for further structural confirmation. A certificate of analysis alone does not guarantee independent verification.
Legality depends on the country and the intended use. In many places it is not approved as a drug and may be regulated as a research chemical. Buyers should check local laws and institutional policies before obtaining it.
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.